343 related articles for article (PubMed ID: 15730862)
21. Intestinal response to myeloablative chemotherapy in piglets.
Pontoppidan PL; Shen RL; Petersen BL; Thymann T; Heilmann C; Müller K; Sangild PT
Exp Biol Med (Maywood); 2014 Jan; 239(1):94-104. PubMed ID: 24304819
[TBL] [Abstract][Full Text] [Related]
22. Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning.
Mehta J; Powles RL; Mitchell P; Rege K; De Lord C; Treleaven J
Bone Marrow Transplant; 1994 May; 13(5):583-7. PubMed ID: 8054911
[TBL] [Abstract][Full Text] [Related]
23. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
[TBL] [Abstract][Full Text] [Related]
25. Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage.
He X; Ye Y; Xu X; Wang J; Huang Y; Weng G; Zhang M; Guo K
Biomed Res Int; 2016; 2016():3071214. PubMed ID: 27843940
[TBL] [Abstract][Full Text] [Related]
26. Effects of bone marrow transplantation and polyinosinic-polycytidylic acid (poly I:C) on the rescue of animals from busulfan-induced NK suppression.
Bhoopalam N; Fried W; Benson D; Barone-Verales J; Price K
Exp Hematol; 1989 May; 17(4):357-63. PubMed ID: 2651135
[TBL] [Abstract][Full Text] [Related]
27. Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients.
Prigozhina TB; Elkin G; Gurevitch O; Morecki S; Yakovlev E; Khitrin S; Slavin S
Blood Cells Mol Dis; 2004; 33(3):238-47. PubMed ID: 15528138
[TBL] [Abstract][Full Text] [Related]
28. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation].
Zhang GC; Zheng D; Guan XX; Luo SK; Li J; Peng AH; Tong XZ; Lai FZ; Tan EX; Hong WD
Ai Zheng; 2003 Jun; 22(6):620-3. PubMed ID: 12948413
[TBL] [Abstract][Full Text] [Related]
30. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
[TBL] [Abstract][Full Text] [Related]
31. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
32. The influence of cyclophosphamide on antibody formation in the mouse.
Willers JM; Sluis E
Ann Immunol (Paris); 1975 Apr; 126(3):267-79. PubMed ID: 1101799
[TBL] [Abstract][Full Text] [Related]
33. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
Kim JG; Sohn SK; Chae YS; Yang DH; Lee JJ; Kim HJ; Shin HJ; Jung JS; Kim WS; Kim DH; Suh C; Kim SJ; Eom HS; Bae SH
Bone Marrow Transplant; 2007 Nov; 40(10):919-24. PubMed ID: 17846602
[TBL] [Abstract][Full Text] [Related]
34. The development of busulfan/cyclophosphamide preparative regimens.
Santos GW
Semin Oncol; 1993 Aug; 20(4 Suppl 4):12-6; quiz 17. PubMed ID: 8342070
[TBL] [Abstract][Full Text] [Related]
35. BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.
Talamo G; Claxton DF; Dougherty DW; Ehmann CW; Sivik J; Drabick JJ; Rybka W
Bone Marrow Transplant; 2009 Aug; 44(3):157-61. PubMed ID: 19204716
[TBL] [Abstract][Full Text] [Related]
36. Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graft-versus-leukaemia effect?
Rassam SM; Katz F; Chessells JM; Morgan G
Bone Marrow Transplant; 1993 Mar; 11(3):247-50. PubMed ID: 8467291
[TBL] [Abstract][Full Text] [Related]
37. Growth of human hematopoietic cells in immunodeficient mice conditioned with cyclophosphamide and busulfan.
Basch RS; Quito FL; Beh J; Hirst JA
Stem Cells; 1997; 15(4):314-23. PubMed ID: 9253116
[TBL] [Abstract][Full Text] [Related]
38. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.
Cantoni N; Gerull S; Heim D; Halter J; Bucher C; Buser A; Tsakiris DA; Passweg J; Tichelli A; Stern M; Gratwohl A
Bone Marrow Transplant; 2011 Mar; 46(3):344-9. PubMed ID: 20548339
[TBL] [Abstract][Full Text] [Related]
39. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation.
Elkin G; Prigozhina TB; Slavin S
Exp Hematol; 2004 Jun; 32(6):579-84. PubMed ID: 15183899
[TBL] [Abstract][Full Text] [Related]
40. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Martino R; Pérez-Simón JA; Moreno E; Queraltó JM; Caballero D; Mateos M; Sureda A; Cañizo C; Brunet S; Briones J; Vazquez L; Clopés A; San Miguel JF; Sierra J
Biol Blood Marrow Transplant; 2005 Jun; 11(6):437-47. PubMed ID: 15931632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]